Hepatitis C News

Statin use significantly decreased decompensation in patients with HBV- and HCV-related cirrhosis, with a borderline effect observed in patients with alcoholic cirrhosis, according to recently published study results.

Treatment with direct-acting antivirals may result in remission of hepatitis C virus-associated lymphoma, researchers suggested.

Post-hepatectomy overall and hepatocellular carcinoma recurrence-free survival rates were significantly higher in patients with hepatitis C who achieved sustained virologic response with pegylated IFN plus ribavirin treatment compared with patients who did not.

The Fibrosis-4 score is more effective than the Child-Turcotte-Pugh and Model for End-Stage Liver Disease scores in predicting complications from hepatitis C virus, according to researchers.

Researchers found significant evidence of elevated rates of subsequent Parkinson’s disease in patients with hepatitis B and hepatitis C, though the underlying correlation is yet to be determined, according to a recently published study.

The National Academies of Science, Engineering and Medicine released phase two of its report outlining a strategy for eliminating viral hepatitis in the United States by 2030 and potentially saving 90,000 lives.

FDA-approved oral direct-acting agent therapy produced high rates of safety, tolerability and efficacy for treating hepatitis C virus infection, especially for patient populations considered difficult to cure, according to research published in Annals of Internal Medicine.

Chronic hepatitis C virus (HCV) infection is a leading cause of cirrhosis, end-stage liver disease, hepatocellular carcinoma, and death from liver disease in the United States. Rapid advancements in the field and interferon-free regimens approved for HCV, as well as several on the horizon, offer improved outcomes, shorter treatment durations, and unique adverse event profiles; therefore, clinicians must stay informed of the evolving data to counsel patients appropriately. Clinicians face challenges regarding how to make treatment choices among the numerous interferon-free regimens to improve treatment uptake and optimize outcomes in patients with HCV. This roundtable discussion among leading experts in HCV was recorded immediately following the 2016 EASL meeting in Barcelona, Spain, exploring some of the most recent findings and addressing the evidence-based clinical application of these data for HCV patients.

In a small cohort study, ribavirin combined with a regimen for HIV-1 and hepatitis C genotype 1 coinfection was safe and effective in patients also receiving Prezista.

Compared with men, women on the waitlist for liver transplantation were less likely to receive exception points or achieve first position and were more likely to be declined an organ offer due to donor–recipient size mismatch, according to results of a retrospective study.